Woodline Partners’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Woodline Partners’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-437,431	Closed	-$39K	–	851
2022 Q2	$39K	Sell	437,431 -552,569	-56%	-$123K	﹤0.01%	645
2022 Q1	$356K	Hold	990,000	–	–	0.01%	527
2021 Q4	$495K	Buy	+990,000	New	+$558K	0.01%	551

Other funds holding CLDI.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Woodline Partners's CLDI.WS Position: Q3 2022 in Review

Woodline Partners sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2022, closing a stake of 437,431 shares — an estimated $39K sold.

Woodline Partners first reported a position in CLDI.WS in Q4 2021 and held it in 3 quarters. The position peaked at $495K in Q4 2021. 26 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2022.

Woodline Partners reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2022 after selling out during the quarter.
Woodline Partners sold 437,431 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2022, an estimated $39K.
Woodline Partners first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 3 quarters.
Woodline Partners's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $495K in Q4 2021.
26 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.